Cite
MLA Citation
J. Gribben et al.. “AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO.” Hematological oncology, vol. 37, n.d., pp. 227–229. http://access.bl.uk/ark:/81055/vdc_100086210468.0x000046